Skip to main content

Aviva to Make Antibodies for ISB's Liver Toxicity Biomarker Program

NEW YORK (GenomeWeb News) - Aviva Systems Biology will produce antibodies that the Institute for Systems Biology will use to identify liver toxicity biomarkers, Aviva said Wednesday.
 
Under the terms of the collaborative agreement, Aviva will develop and produce the antibodies from a list of proteins provided by the ISB.
 
ISB will then assess the efficacy of these antibodies and will use them to find biomarker proteins that work as early liver toxicity biomarkers.
 
Aviva said the antibodies will be used in surface plasmon resonance imaging, a method of detecting proteins at density levels lower than is currently possible with mass spectrometry and other technologies.
 
Aviva said it has an inventory of more than 12,000 target peptide-specific antibodies that represent over 4,000 human and mouse targets.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.